FDA Rejects Vanda's Hetlioz for Jet Lag—Shares Drop 12%

Vanda Pharmaceuticals stock falls in premarket trading after FDA denies Hetlioz approval for jet lag disorder, citing clinical trial design concerns despite positive efficacy data.